Continuous Glucose Monitoring for Type 2 Diabetes: How Does It Compare with Type 1 Diabetes?

Martens T , Beck RW , Bailey R , et al.: Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a Randomized Clinical Trial. JAMA, 2021; 325:2262–2272.

The Diabetes Control and Complications Trial Research Group: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes, 1995; 44:968–983.

Beck RW , Riddlesworth TD , Ruedy K , et al.: Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med, 2017; 167:365–374.

Karter AJ , Parker MM , Moffet HH , et al.: Association of real-time continuous glucose monitoring with glycemic control and acute metabolic events among patients with insulin-treated diabetes. JAMA, 2021; 325:2273–2284.

Yaron M , Roitman E , Aharon-Hananel G , et al.: Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care, 2019; 42:1178–1184.

Haak T , Hanaire H , Ajjan R , et al.: Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a Multicenter, Open-Label Randomized Controlled Trial. Diabetes Ther, 2017; 8:55–73.

Elliott T , Beca S , Beharry R , et al.: The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: a retrospective real-world chart review study. Diab Vasc Dis Res, 2021; 18:14791641211021374.

Wright EE Jr , Kerr MSD , Reyes IJ , et al.: Use of flash continuous glucose monitoring is associated with A1C reduction in people with type 2 diabetes treated with basal insulin or noninsulin therapy. Diabetes Spectr, 2021; 34:184–189.

Dicembrini I , Mannucci E , Monami M , Pala L : Impact of technology on glycaemic control in type 2 diabetes: a meta-analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion. Diabetes Obes Metab, 2019; 21:2619–2625.

Ida S , Kaneko R , Murata K : Utility of real-time and retrospective continuous glucose monitoring in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. J Diabetes Res, 2019; 2019:4684815.

Gavin JR , Bailey C : Real-world studies support use of CGM in type 1 and type 2 diabetes independently of treatment regimen. Diabetes Technol Ther, 2021; 23:S19–S27.

Puhr S , Welsh JB , Bauza CE , Walker TC : Patients with type 2 diabetes and residual insulin secretory capacity realize glycemic benefits from real-time continuous glucose monitoring. J Diabetes Sci Technol, 2021; 15:965–967.

Bailey R , Calhoun P , Chao C , Walker TC : With or without residual C-peptide , patients with type 2 diabetes realize glycemic benefits from real-time continuous glucose monitoring. Diabetes Technol Ther 2022; doi: 10.1089/dia.2021.0384.

Wada E , Onoue T , Kobayashi T , et al.: Flash glucose monitoring helps achieve better glycemic control than conventional self-monitoring of blood glucose in non-insulin-treated type 2 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care, 2020; 8:e001115.

Jackson MA , Ahmann A , Shah VN : Type 2 diabetes and the use of real-time continuous glucose monitoring. Diabetes Technol Ther, 2021; 23:S27–S34.

Park C , Le QA : The effectiveness of continuous glucose monitoring in patients with type 2 diabetes: a systematic review of literature and meta-analysis. Diabetes Technol Ther, 2018; 20:613–621.

Ehrhardt N , Al Zaghal E : Continuous glucose monitoring as a behavior modification tool. Clin Diabetes, 2020; 38:126–131.

Kroger J , Siegmund T , Schubert-Olesen O , et al.: AGP and nutrition—analysing postprandial glucose courses with CGM. Diabetes Res Clin Pract, 2021; 174:108738.

Zeevi D , Korem T , Zmora N , et al.: Personalized nutrition by prediction of glycemic responses. Cell, 2015; 163:1079–1094.

Bergenstal RM , Kerr MSD , Roberts GJ , et al.: Flash CGM is associated with reduced diabetes events and hospitalizations in insulin-treated type 2 diabetes. J Endocr Soc, 2021; 5:bvab013.

Selvin E , Parrinello CM , Daya N , Bergenstal RM : Trends in insulin use and diabetes control in the U.S.: 1988–1994 and 1999–2012. Diabetes Care, 2016; 39:e33–e35.

Kazemian P , Shebl FM , McCann N , et al.: Evaluation of the cascade of diabetes care in the United States, 2005–2016. JAMA Intern Med, 2019; 179:1376–1385.

Fang M , Wang D , Coresh J , Selvin E : Trends in diabetes treatment and control in U.S. Adults, 1999–2018. N Engl J Med, 2021; 384:2219–2228.

Monnier L , Colette C , Dunseath GJ , Owens DR : The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care, 2007; 30:263–269.

Monnier L , Colette C , Dejager S , Owens D : Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes. Diabetes Care, 2013; 36:4057–4062.

Bergenstal RM , Layne JE , Zisser H , et al.: Remote application and use of real-time continuous glucose monitoring by adults with type 2 diabetes in a Virtual Diabetes Clinic. Diabetes Technol Ther, 2021; 23:128–132.

Dixon RF , Zisser H , Layne JE , et al.: A virtual type 2 diabetes clinic using continuous glucose monitoring and endocrinology visits. J Diabetes Sci Technol, 2020; 14:908–911.

Gal RL , Cohen NJ , Kruger D , et al.: Diabetes Telehealth Solutions: improving self-management through remote initiation of continuous glucose monitoring. J Endocr Soc, 2020; 4:bvaa076.

American Diabetes Diabetes Technology: Standards of medical care in diabetes-2021. Diabetes Care, 2021; 44:S85–S99.

Grunberger G , Sherr J , Allende M , et al.: American Association of Clinical Endocrinology Clinical Practice Guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract, 2021; 27:505–537.